To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and economic issues associated with sirolimus, the most recent immunosuppressive agent approved for kidney transplantation.
DATA SOURCES:
A MEDLINE search (1966–June 2000) was completed to identify primary and review articles. In addition, abstracts from recent meetings on transplantation were reviewed for information and research on sirolimus.
STUDY SELECTION AND DATA EXTRACTION:
Blinded, randomized, controlled studies were the goal, but, as with most newly approved immunosuppressive agents, a significant amount of information on sirolimus is not available in this optimal form. All articles were assessed and all pertinent information was incorporated in this review.
DATA SYNTHESIS:
Sirolimus is structurally related to the immunosuppressive agent tacrolimus, and retains a pharmacokinetic and drug interaction profile similar to that of the calcineurin inhibitors, cyclosporine and tacrolimus. However, the novel mechanism of action of sirolimus differs significantly from these agents, as does its adverse effect profile. The most significant adverse reaction is hyperlipidemia. Clinical experience with sirolimus has allowed transplant centers to expand its use into other areas of transplantation as well as certain autoimmune disorders.
CONCLUSIONS:
The definitive role of sirolimus will continue to be determined; however, sirolimus offers an excellent addition to the transplant immunosuppression armamentarium.
VézinaCKudelskiASehgalSN. Rapamycin (AY-22,989), a new antifungal antibiotic I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot1975;28:721–6.
2.
SehgalSNBakerHVézinaC. Rapamycin (AY-22,989), a new antifungal antibiotic II. Fermentation, isolation, and characterization. J Antibiot1975;28:727–31.
3.
ChenHWuJXuDLuoHDalozePM. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Transplantation1993;56:661–6.
4.
SeufferleinTRozengurtE. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res1996;270:815–22.
5.
ShiYFrankelARadnayiLGPennLZMillerRGMillsGB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res1995;55:1982–8.
6.
AbrahamRT. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol1998;10:330–6.
7.
Vilella-BachMNuzziPFangYChenJ. The FKBP12-rapamycin— Binding domain is required for FKBP12-rapamycin—associated protein kinase activity and G1 progression. J Biol Chem1999;274:4266–72.
8.
SehgalSN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem1998;31:335–40.
9.
LawrenceJCJrAbrahamRT. PHAS/4E-BPs as regulators of mRNA translation and cell proliferation. Trends Biochem Sci1997;22:345–9.
10.
SehgalSN. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit1995;17:660–5.
11.
YatscoffRW. Pharmacokinetics of rapamycin. Transplant Proc1996;28: 970–3.
12.
BrattströmCTydénGSäweJHerleniusGClaessonKGrothCG. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc1996;28:985–6.
13.
JohnsonEMZimmermanJDuderstadtKChambersJSorensonALGrangerDKA randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc1996;28:987.
14.
TrepanierDJGallantHLegattDFYatscoffRW. Rapamycin: Distribution, pharmacokinetics and therapeutic range investigations: An update. Clin Biochem1998;31:345–51.
15.
ZimmermanJJKahanBD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol1997;37:405–15.
16.
FerronGMMishinaE VZimmermanJJJuskoWJ. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther1997;61:416–28.
17.
YatscoffRWAspesletLJ. The monitoring of immunosuppressive drugs: A pharmacodynamic approach. Ther Drug Monit1998;20:459–63.
KaplanBMeier-KriescheHUNapoliKLKahanBD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther1998;63:48–53.
20.
KimballPMKermanRHKahanBD. Production of synergistic but non-identical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation1991;51:486–90.
21.
KahanBD. Emerging strategies for the clinical application of rapamycin. Clin Biochem1998;31:341–4.
22.
CampanaCRegazziMBBuggiaIMolinaroM. Clinically significant drug interactions with cyclosporine. An update. Clin Pharmacokinet1996;30:141–79.
23.
DumontFJMelinoMRStaruchMJKoprakSLFischerPASigalNH. The immunosuppressive macrolides FK506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol1990;144:1418–24.
24.
DumontFJStaruchMJKoprakSLSiekierkaJJLinCSHarrisonRThe immunosuppressive and toxic effects of FK506 are mechanistically related: Pharmacology of a novel antagonist of FK506 and rapamycin. J Exp Med1992;176:751–60.
25.
VuMDQiSDashengXWuJFitzsimmonsWESehgalSNTacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation1997;64:1853–6.
26.
MahalatiKMcAlisterVPeltekianKDominguezJGaoZHMacDonaldAS. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression (abstract 105). Transplantation1999;67:S33.
SlatonJWKahanBD. Case report — Sirolimus rescue therapy for refractory renal allograft rejection. Transplantation1996;61:977–9.
29.
BranisteanuDDMathieuCBouillonR. Synergism between sirolimus and 1,25-dihydroxyvitamin D3 in vitro and in vivo. J Neuroimmun1997;79:138–47.
30.
KahanBD, for the USA Rapamune Study Group. Pivotal Phase III multicenter, randomized blinded trial of sirolimus versus azathioprine in combination with cyclosporine and prednisone in primary renal transplants (abstract 68). Transplantation1999;67:S559.
31.
MacDonaldAS, for the Rapamune Global Study Group. A randomized trial of sirolimus, cyclosporine, and prednisone vs cyclosporine—prednisone alone in recipients of mismatched first kidney grafts: Results at one year (abstract 2). Transplantation1999;67:S545.
32.
MathewTH, for the Rapamune Global Study Group. The safety and efficacy of sirolimus/cyclosporine for the prevention of acute rejection in primary renal allograft recipients (abstract 957). Transplantation2000;69:S360.
33.
NeylanJFWickershamPJaffeF. Effect of race on efficacy and safety of sirolimus vs aza + standard immunotherapy in renal transplantation (abstract 924). Transplantation1999;67:S237.
34.
Rapamune 5-mg dose needs more data in high-risk transplants, cmte. says. The pink sheet.1999;61(August 2):10–1.
35.
SindhiRWickershamPSJaffeJSScarolaJ. Outcomes of African Americans (aa) in a Phase III randomized placebo-controlled trial of sirolimus (srl) in renal transplantation (abstract 925). Transplantation1999;67:S238.
36.
KahanBD, for the US and Global Multicenter Sirolimus Trial Groups. Two-year follow-up of the pivotal multicenter trials of sirolimus (abstract 960). Transplantation2000;69:S361.
37.
HongKKahanBD. Sirolimus rescue therapy for refractory rejection in renal transplantation (abstract 963). Transplantation2000;69;S362.
38.
KahanBDPescovitzMChanGNeylanJJulianBKatzSMOne-year outcome after steroid withdrawal from a sirolimus—cyclosporine—prednisone regimen in cadaver- and living-donor transplant recipients (abstract 658). Transplantation1998;66:S167.
39.
HongJCKahanBD. Use of anti-cd25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation1999;68:701–4.
40.
GrothCGBäckmanLMoralesJMCalneRKreisHLangPSirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation1999;67:1036–42.
41.
KriesHCisterneJMLandWWramnerLSquiffletJPAbramowiczDSirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation2000;69:1252–60.
42.
WatsonCJEFriendPJJamiesonNVFrickTWAlexanderGGimsonAESirolimus: A potent new immunosuppressant for liver transplantation. Transplantation1999;67:505–9.
43.
KnetemanNMeebergGBonarSBainVMaMIssaSSirolimus-based immunosuppression for liver transplantation with preexisting malignancy (abstract 780). Transplantation1999;67:S201.
44.
McAlisterVCPeltekianKGaoZBitter-SuermannHMacDonaldAS. The use of sirolimus in liver transplant recipients (abstract 10). Liver Transplant Surg1999;5:C-3.
45.
MillerLBrozenaSValentineH, for the Rapamycin Investigators. Treatment of acute cardiac allograft rejection with rapamycin: A multicenter dose ranging study (abstract 13). J Heart Lung Transplant1997;16:44.
46.
GregoryCRHuiePBillinghamMEMorrisRE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Transplantation1993;55:1409–18.
47.
MeiserBMBillinghamMEMorrisRE. Effects of cyclosporin, FK506, and rapamycin on graft—vessel disease. Lancet1991;338:1297–8.
48.
GregoryCRHuangXPrattREDzauVJShorthouseRBillinghamMETreatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation1995;59:655–61.
49.
KahanBD. The role of rapamycin in chronic rejection prophylaxis: A theoretical consideration. Graft1998;1:93–6.
50.
DunitzJBolmanRMParkSGibsonCKnopikSStegerMSirolimus-based immune suppression in lung transplant recipients (abstract 385). Transplantation1999;67:S103.
51.
MerkelPALetourneauENPolissonRP. Investigational agents for rheumatoid arthritis. Rheumatic Dis Clin North Am1995;21:779–96.
52.
YocumDE. The use of immunomodulators in early rheumatoid arthritis. Semin Arthritis Rheum1994;23(suppl 2):44–9.
53.
BurkhardtHKaldenJR. Xenobiotic immunosuppressive agents: Therapeutic effects in animal models of autoimmune diseases. Rheumatol Int1997;17:85–90.
54.
BaederWLSredyJSehgalSNChangJYAdamsLM. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol1992;89:174–8.
55.
WarnerLMAdamsLMSehgalSN. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum1994;37:289–97.
56.
CarlsonRPHartmanDATomchekLAWalterTLLugayJRCalhounWRapamycin, a potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther1993;266:1125–38.
57.
MartinDFDeBargeLRNussenblattRBChanCCRobergeFG. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol1995;154:922–7.
58.
AndohTFLindsleyJFransechiniNBennettWM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation1996;62:311–6.
59.
AndohTFBurdmannEAFransechiniNHoughtonDCBennettWM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int1996;50:1110–7.
60.
PodderHStepkowskiSMNapoliKLKahanBD. Sirolimus exacerbates CsA-induced nephrotoxicity by raising CsA blood trough levels, but does not impair renal function by a pharmacodynamic interaction (abstract 206). Transplantation1999;67:S58.
61.
MoralesJMWramnerLKreisHDurandDCampistolJMAndresA, for the Sirolimus European Renal Transplant Study Group. Sirolimus does not exhibit the nephrotoxicity associated with cyclosporine administration: Pooled data analysis of two randomized Phase II trials in renal transplant recipients (abstract 848). Transplantation2000;69:S332.
62.
BrattströmCWilczekHETydénGBöttigerYSäweJGrothCG. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc1998;30:3950–1.
63.
BrattströmCWilczekHTydénGBöttigerYSäweJGrothCG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation1998;65:1272–4.
64.
MurgiaMGJordanSKahanBD. The side effect profile of sirolimus: A Phase I study in quiescent cyclosporine—prednisone—treated renal transplant patients. Kidney Int1996;49:209–16.
65.
KahanBDPodbielskiJNapoliKLKatzSMMeier-KriescheHUVan BurenCT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation1998;66:1040–6.
66.
KahanBD. Rapamycin: Personal algorithms for use based on 250 treated renal allograft recipients. Transplant Proc1998;30:2185–8.
67.
KahanBDJaffeJS. Triglyceride (tg) elevations in renal transplant recipients treated with sirolimus (rapamycin, rapa) added to a cyclosporine (csa)/prednisone (pred) regimen (abstract 172). Transplantation1999;67:S585.
68.
DiményETufvesonGLithellHLarssonESiegbahnAFellströmB. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest1993;23:572–9.
69.
MassyZADebandtJPTheveninMMorelonELacourBKreisH. Hyperlipidemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or ciclosporin a (abstract 635). Transplantation1999;67:S165.
70.
MorrisettJDBallantyneCMPownallHJOpekunARJaffeJSOppermannSEffect of sirolimus on plasma lipid and lipoprotein levels and metabolism in renal transplant patients (abstract 213). Transplantation1999;67:S60.
71.
MayerD. Which immunosuppression?Transplantation1999;67:937–8.
72.
KahanBDPodbielskiJNapoliKLKatzSMMeier-KriescheHUVan BurenCT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation1998;66:1040–6.
73.
NapoliKLKahanBD. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection. Clin Chem1996;42:1944.
74.
KahanBDNapoliKL. Role of therapeutic drug monitoring of rapamycin. Transplant Proc1998;30:2189–91.
75.
ManninenDDongFWangF, for the Rapamune US Study Group. Economic evaluation of sirolimus therapy in the first year following renal transplantation (abstract 871). Transplantation2000;69:S337.
